Pharmacogenomics of heart failure - Focus on drug disposition and action

Cardiovascular Research

Volumn 64, Issue 1, 2004, Pages 32-39

  Cascorbi, Ingolf ^a   Paul, Martin ^b   Kroemer, Heyo K ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Adrenergic antagonists; Gene polymorphism; Heart failure; Pharmacokinetics; Renin angiotensin system

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADRENERGIC RECEPTOR BLOCKING AGENT; ALDOSTERONE ANTAGONIST; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR; BISOPROLOL; CARRIER PROTEIN; CARVEDILOL; CELIPROLOL; CYTOCHROME P450; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN; ENZYME; GLYCOPROTEIN P; IRBESARTAN; LOSARTAN; METOPROLOL; MEVINOLIN; PAFENOLOL; SIMVASTATIN; TALINOLOL;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DNA MODIFICATION; DRUG ACTIVITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG METABOLISM; DRUG TARGETING; GENE FUNCTION; GENE MUTATION; GENE TECHNOLOGY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC TRAIT; GENETIC VARIABILITY; HEART FAILURE; HUMAN; HYPERTENSION; OUTCOMES RESEARCH; PATIENT; PHARMACOGENOMICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SURVIVAL; TREATMENT OUTCOME;

ALDOSTERONE; CARDIOVASCULAR AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIUM; PEPTIDYL-DIPEPTIDASE A; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM;

EID: 4544260516     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2004.06.003     Document Type: Review

References (102)

1. Charron P., Komajda M. Genes and their polymorphisms in mono-and multifactorial cardiomyopathies: towards pharmacogenomics in heart failure. Pharmacogenomics. 3:2002;367-378
2. Feldman A.M. The emerging role of pharmacogenomics in the treatment of patients with heart failure. Ann. Thorac. Surg. 76:2003;S2246-S2253
3. Hunt S.A., Baker D.W., Chin M.H., et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. J. Heart Lung Transplant. 21:2002;189-203
4. Hall A.S., Murray G.D., Ball S.G. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) study. acute infarction ramipril efficacy. Lancet. 349:1997;1493-1497
5. Cohn J.N., Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 345:2001;1667-1675
6. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 353:1999;9-13
7. The Digitalis Investigation Group The effect of digoxin on mortality and morbidity in patients with heart failure. N. Engl. J. Med. 336:1997;525-533
8. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341:1999;709-717
9. Rich S., McLaughlin V.V. Endothelin receptor blockers in cardiovascular disease. Circulation. 108:2003;2184-2190
10. Hjalmarson A., Goldstein S., Fagerberg B., et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 283:2000;1295-1302
11. Lechat P., Escolano S., Golmard J.L., et al. Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the cardiac insufficiency bisoprolol study (CIBIS). Circulation. 96:1997;2197-2205
12. Packer M., Fowler M.B., Roecker E.B., et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 106:2002;2194-2199
13. Oldham H.G., Clarke S.E. In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol. Drug Metab. Dispos. 25:1997;970-977
14. Pepper J.M., Lennard M.S., Tucker G.T., Woods H.F. Effect of steroids on the cytochrome P4502D6-catalysed metabolism of metoprolol metabolism persists during long-term treatment. Pharmacogenetics. 1:1991;119-122
15. Rau T., Heide R., Bergmann K., et al. Effect of the CYP2D6 genotype on metoprolol. Pharmacogenetics. 12:2002;465-472
16. Wuttke H., Rau T., Heide R., et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin. Pharmacol. Ther. 72:2002;429-437
17. Aklillu E., Persson I., Bertilsson L., et al. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J. Pharmacol. Exp.Ther. 278:1996;441-446
18. Giessmann T., Modess C., Hecker U., et al. CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects. Clin. Pharmacol. Ther. 75:2004;213-222
19. Hallberg P., Karlsson J., Kurland L., et al. The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish irbesartan left ventricular hypertrophy investigation vs. atenolol (SILVHIA) trial. J. Hypertens. 20:2002;2089-2093
20. Lee C.R., Pieper J.A., Hinderliter A.L., Blaisdell J.A., Goldstein J.A. Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and*1/*3 individuals. Pharmacotherapy. 23:2003;720-725
21. Yasar U., Tybring G., Hidestrand M., et al. Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab. Dispos. 29:2001;1051-1056
22. Sekino K., Kubota T., Okada Y., et al. Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects. Eur. J. Clin. Pharmacol. 59:2003;589-592
23. Schinkel A.H., Wagenaar E., Mol C.A., van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 97:1996;2517-2524
24. Terao T., Hisanaga E., Sai Y., Tamai I., Tsuji A. Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J. Pharm. Pharmacol. 48:1996;1083-1089
25. Zhang Y., Benet L.Z. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin. Pharmacokinet. 40:2001;159-168
26. Pauli-Magnus C., von Richter O., Burk O., et al. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J. Pharmacol. Exp. Ther. 293:2000;376-382
27. Fromm M.F., Kauffmann H.M., Fritz P., et al. The effect of rifampin treatment on intestinal expression of human MRP transporters. Am. J. Pathol. 157:2000;1575-1580
28. Greiner B., Eichelbaum M., Fritz P., et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 104:1999;147-153
29. Geick A., Eichelbaum M., Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J. Biol. Chem. 276:2001;14581-14587
30. Schuetz E.G., Furuya K.N., Schuetz J.D. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J. Pharmacol. Exp. Ther. 275:1995;1011-1018
31. Hoffmeyer S., Burk O., von Richter O., et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U. S. A. 97:2000;3473-3478
32. Cascorbi I., Gerloff T., Johne A., et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin. Pharmacol. Ther. 69:2001;169-174
33. Ameyaw M.M., Regateiro F., Li T., et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics. 11:2001;217-221
34. Kim R.B., Leake B.F., Choo E.F., et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 70:2001;189-199
35. Schaeffeler E., Eichelbaum M., Brinkmann U., et al. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet. 358:2001;383-384
36. Johne A., Kopke K., Gerloff T., et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin. Pharmacol. Ther. 72:2002;584-594
37. Verstuyft C., Schwab M., Schaeffeler E., et al. Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur. J. Clin. Pharmacol. 58:2003;809-812
38. Moriya Y., Nakamura T., Horinouchi M., et al. Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol. Pharm. Bull. 25:2002;1356-1359
39. Sakaeda T., Nakamura T., Horinouchi M., et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm. Res. 18:2001;1400-1404
40. Siegmund W., Ludwig K., Giessmann T., et al. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin. Pharmacol. Ther. 72:2002;572-583
41. Meissner K., Sperker B., Karsten C., et al. Expression and localization of P-glycoprotein in human heart: effects of cardiomyopathy. J. Histochem. Cytochem. 50:2002;1351-1356
42. Meissner K., Jedlitschky G., Zu Schwabedissen H.M., et al. Modulation of MDR1 (ABCB1) expression in human heart: by hereditary polymorphisms. Pharmacogenetics. 14:2004;381-385
43. Bristow M.R., Minobe W.A., Raynolds M.V., et al. Reduced beta 1 receptor messenger RNA abundance in the failing human heart. J. Clin. Invest. 92:1993;2737-2745
44. Koch W.J., Lefkowitz R.J., Rockman H.A. Functional consequences of altering myocardial adrenergic receptor signaling. Annu. Rev. Physiol. 62:2000;237-260
45. Hein L. Physiological significance of beta-adrenergic receptor polymorphisms: in-vivo or in-vitro veritas? Pharmacogenetics. 11:2001;187-189
46. Mason D.A., Moore J.D., Green S.A., Liggett S.B. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J. Biol. Chem. 274:1999;12670-12674
47. Wagoner L.E., Craft L.L., Zengel P., et al. Polymorphisms of the beta1-adrenergic receptor predict exercise capacity in heart failure. Am. Heart J. 144:2002;840-846
48. Mialet P.J., Rathz D.A., Petrashevskaya N.N., et al. Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat. Med. 9:2003;1300-1305
49. White H.L., de Boer R.A., Maqbool A., et al. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur. J. Heart Fail. 5:2003;463-468
50. Small K.M., Wagoner L.E., Levin A.M., Kardia S.L., Liggett S.B. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N. Engl. J. Med. 347:2002;1135-1142
51. Wagoner L.E., Craft L.L., Singh B., et al. Polymorphisms of the beta(2)-adrenergic receptor determine exercise capacity in patients with heart failure. Circ. Res. 86:2000;834-840
52. Dzau V.J. Vascular renin-angiotensin system and vascular protection. J. Cardiovasc. Pharmacol. 22(Suppl 5):1993;S1-S9
53. Villard E., Lalau J.D., van Hooft I.S., et al. A mutant renin gene in familial elevation of prorenin. J. Biol. Chem. 269:1994;30307-30312
54. Fuchs S., Philippe J., Germain S., et al. Functionality of two new polymorphisms in the human renin gene enhancer region. J. Hypertens. 20:2002;2391-2398
55. Hasimu B., Nakayama T., Mizutani Y., et al. Haplotype analysis of the human renin gene and essential hypertension. Hypertension. 41:2003;308-312
56. Fernandez-Arcas N., Dieguez-Lucena J.L., Munoz-Moran E., et al. Both alleles of the M235T polymorphism of the angiotensinogen gene can be a risk factor for myocardial infarction. Clin. Genet. 60:2001;52-57
57. Ishigami T., Umemura S., Iwamoto T., et al. Molecular variant of angiotensinogen gene is associated with coronary atherosclerosis. Circulation. 91:1995;951-954
58. Tiret L., Mallet C., Poirier O., et al. Lack of association between polymorphisms of eight candidate genes and idiopathic dilated cardiomyopathy: the CARDIGENE study. J. Am. Coll. Cardiol. 35:2000;29-35
59. Goldbergova M., Spinarova L., Spinar J., et al. Association of two angiotensinogen gene polymorphisms, M235T and G(-6)A, with chronic heart failure. Int. J. Cardiol. 89:2003;267-272
60. Rigat B., Hubert C., Alhenc-Gelas F., et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest. 86:1990;1343-1346
61. Cambien F., Poirier O., Lecerf L., et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 359:1992;641-644
62. Lindpaintner K., Pfeffer M.A., Kreutz R., et al. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N. Engl. J. Med. 332:1995;706-711
63. Holmer S.R., Bickeboller H., Hengstenberg C., et al. Angiotensin converting enzyme gene polymorphism and myocardial infarction a large association and linkage study. Int. J. Biochem. Cell Biol. 35:2003;955-962
64. Samani N.J., Thompson J.R., O'Toole L., Channer K., Woods K.L. A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation. 94:1996;708-712
65. Schunkert H. Polymorphism of the angiotensin-converting enzyme gene and cardiovascular disease. J. Mol. Med. 75:1997;867-875
66. Montgomery H.E., Clarkson P., Dollery C.M., et al. Association of angiotensin-converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training. Circulation. 96:1997;741-747
67. Montgomery H., Brull D., Humphries S.E. Analysis of gene-environment interactions by "stressing-the-genotype" studies: the angiotensin converting enzyme and exercise-induced left ventricular hypertrophy as an example. Ital. Heart J. 3:2002;10-14
68. Fatini C., Guazzelli R., Manetti P., et al. RAS genes influence exercise-induced left ventricular hypertrophy: an elite athletes study. Med. Sci. Sports Exerc. 32:2000;1868-1872
69. Hagberg J.M., Ferrell R.E., Dengel D.R., Wilund K.R. Exercise training-induced blood pressure and plasma lipid improvements in hypertensives may be genotype dependent. Hypertension. 34:1999;18-23
70. Rankinen T., Gagnon J., Perusse L., et al. AGT M235T and ACE ID polymorphisms and exercise blood pressure in the HERITAGE Family Study. Am. J. Physiol., Heart Circ. Physiol. 279:2000;H368-H374
71. Fuentes R.M., Perola M., Nissinen A., Tuomilehto J. ACE gene and physical activity, blood pressure, and hypertension: a population study in Finland. J. Appl. Physiol. 92:2002;2508-2512
72. Jalil J.E., Cordova S., Ocaranza M., et al. Angiotensin I-converting enzyme insertion/deletion polymorphism and adrenergic response to exercise in hypertensive patients. Med. Sci. Monit. 8:2002;CR566-CR571
73. Sonna L.A., Sharp M.A., Knapik J.J., et al. Angiotensin-converting enzyme genotype and physical performance during US Army basic training. J. Appl. Physiol. 91:2001;1355-1363
74. van Berlo J.H., Pinto Y.M. Polymorphisms in the RAS and cardiac function. Int. J. Biochem. Cell Biol. 35:2003;932-943
75. Andersson B., Sylven C. The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure. J. Am. Coll. Cardiol. 28:1996;162-167
76. Koopmans R.P., Insel P.A., Michel M.C. Pharmacogenetics of hypertension treatment: a structured review. Pharmacogenetics. 13:2003;705-713
77. Niu T., Chen X., Xu X. Angiotensin converting enzyme gene insertion/deletion polymorphism and cardiovascular disease: therapeutic implications. Drugs. 62:2002;977-993
78. Berge K., Bohn M., Berg K. DNA polymorphism at the locus for angiotensinogen I-converting enzyme in Norwegian patients with myocardial and controls. Clin. Genet. 46:1994;102-104
79. Stangl K., Cascorbi I., Stangl V., et al. A1166C polymorphism of the angiotensin II type 1 receptor gene and risk of adverse events after coronary catheter interventions. Am. Heart J. 140:2000;170-175
80. Diez J., Laviades C., Orbe J., et al. The A1166C polymorphism of the AT1 receptor gene is associated with collagen type I synthesis and myocardial stiffness in hypertensives. J. Hypertens. 21:2003;2085-2092
81. Staessen J.A., Wang J.G., Brand E., et al. Effects of three candidate genes on prevalence and incidence of hypertension in a Caucasian population. J. Hypertens. 19:2001;1349-1358
82. Inoue A., Yanagisawa M., Takuwa Y., et al. The human preproendothelin-1 gene. Complete nucleotide sequence and regulation of expression. J. Biol. Chem. 264:1989;14954-14959
83. Cambien F., Poirier O., Nicaud V., et al. Sequence diversity in 36 candidate genes for cardiovascular disorders. Am. J. Hum. Genet. 65:1999;183-191
84. Nicaud V., Poirier O., Behague I., et al. Polymorphisms of the endothelin-A and -B receptor genes in relation to blood pressure and myocardial infarction: the Etude Cas-Temoins sur l'Infarctus du Myocarde (ECTIM) Study. Am. J. Hypertens. 12:1999;304-310
85. Lajemi M., Gautier S., Poirier O., et al. Endothelin gene variants and aortic and cardiac structure in never-treated hypertensives. Am. J. Hypertens. 14:2001;755-760
86. Charron P., Tesson F., Poirier O., et al. Identification of a genetic risk factor for idiopathic dilated cardiomyopathy. Involvement of a polymorphism in the endothelin receptor type A gene. CARDIGENE group. Eur. Heart J. 20:1999;1587-1591
87. Stevens P.A., Brown M.J. Genetic variability of the ET-1 and the ETA receptor genes in essential hypertension. J. Cardiovasc. Pharmacol. 26(Suppl 3):1995;S9-S12
88. Popowski K., Sperker B., Kroemer H.K., et al. Functional significance of a hereditary adenine insertion variant in the 5′-UTR of the endothelin-1 gene. Pharmacogenetics. 13:2003;445-451
89. Pacher R., Stanek B., Hulsmann M., et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J. Am. Coll. Cardiol. 27:1996;633-641
90. Furchgott R.F., Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 288:1980;373-376
91. Li H., Wallerath T., Munzel T., Forstermann U. Regulation of endothelial-type NO synthase expression in pathophysiology and in response to drugs. Nitric Oxide. 7:2002;149-164
92. Hingorani A.D., Liang C.F., Fatibene J., et al. A common variant of the endothelial nitric oxide synthase (Glu298→Asp) is a major risk factor for coronary artery disease in the UK. Circulation. 100:1999;1515-1520
93. Nadaud S., Bonnardeaux A., Lathrop M., Soubrier F. Gene structure, polymorphism and mapping of the human endothelial nitric oxide synthase gene. Biochem. Biophys. Res. Commun. 198:1994;1027-1033
94. Stangl K., Cascorbi I., Laule M., et al. High CA repeat numbers in intron 13 of the endothelial nitric oxide synthase gene and increased risk of coronary artery disease. Pharmacogenetics. 10:2000;133-140
95. Hui J., Stangl K., Lane W.S., Bindereif A. HnRNP L stimulates splicing of the eNOS gene by binding to variable-length CA repeats. Nat. Struct. Biol. 10:2003;33-37
96. Feng Q., Song W., Lu X., et al. Development of heart failure and congenital septal defects in mice lacking endothelial nitric oxide synthase. Circulation. 106:2002;873-879
97. Jones S.P., Greer J.J., van Haperen R., et al. Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice. Proc. Natl. Acad. Sci. U. S. A. 100:2003;4891-4896
98. Stanssens P., Zabeau M., Meersseman G., et al. High-throughput MALDI-TOF discovery of genomic sequence polymorphisms. Genome Res. 14:2004;126-133
99. Lavebratt C., Sengul S., Jansson M., Schalling M. Pyrosequencing-based SNP allele frequency estimation in DNA pools. Hum. Mutat. 23:2004;92-97
100. Matsuzaki H., Loi H., Dong S., et al. Parallel genotyping of over 10,000 SNPs using a one-primer assay on a high-density oligonucleotide array. Genome Res. 14:2004;414-425
101. Peltonen L. GenomEUtwin: a strategy to identify genetic influences on health and disease. Twin Res. 6:2003;354-360
102. Mwinyi J., Johne A., Bauer S., Roots I., Gerloff T. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin. Pharmacol. Ther. 75:2004;415-421